Aztreonam lysine

ApprovedSmall molecule

Gilead

Aztreonam lysine is one of 118 small molecule programs targeting Bronchiolitis Obliterans. It is currently in Approved.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchiolitis ObliteransActive, not recruiting

BronchiectasisActive, not recruiting

Pseudomonas InfectionActive, not recruiting

Cystic FibrosisActive, not recruiting

Ventilator-Associated PneumoniaActive, not recruiting

Bronchiolitis ObliteransApproved

Active, not recruiting

BronchiectasisApproved

Active, not recruiting

Pseudomonas InfectionPhase 2

Active, not recruiting

Cystic FibrosisPreclinical

Active, not recruiting

Ventilator-Associated PneumoniaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Aztreonam lysine

Gilead

Approved

5 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 6

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Capromorelin

UUniversity of Aarhus

Preclinical

1 8

Advil

KKenvue Brands

Preclinical

1 9

Tums

Otsuka

Preclinical

1 10

Feosol

AAuerbach Hematology Oncology Associates P C

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystic Fibrosis5 trials

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

Completed· Gilead logo

Gilead·Phase 2·NCT01055847·105 enrolled

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

Approved for marketing· Gilead logo

Gilead··NCT00499720

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Completed· Gilead logo

Gilead·Phase 3·NCT00757237·274 enrolled

Show 2 more trials

Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis

Completed· Novartis logo

Novartis··NCT01460836

Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis

Approved for marketing· Gilead logo

Gilead··NCT00989807

Pseudomonas infection1 trial

Aztreonam Lysine for Pseudomonas Infection Eradication Study

Completed· Gilead logo

Gilead·Phase 2·NCT01375049·105 enrolled

Bronchiolitis Obliterans1 trial

Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)

Completed·—·Phase 4·NCT01469364·30 enrolled

Ventilator-Associated Pneumonia1 trial

Nebulized Aztreonam for Prevention of Gram Negative Ventilator-associated Pneumonia

Terminated·—·Phase 2/3·NCT03749226·9 enrolled

Bronchiectasis1 trial

Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Terminated·UUniversity of Dundee·Phase 4·NCT03696290·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Aztreonam lysine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aztreonam lysine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aztreonam lysine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Gilead

Aztreonam lysine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystic Fibrosis5 trials

Pseudomonas infection1 trial

Bronchiolitis Obliterans1 trial

Ventilator-Associated Pneumonia1 trial

Bronchiectasis1 trial

References

Drug Info

Quick Facts

Related News